At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age
In Brief
A Phase 4 clinical trial evaluating ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed and DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed for Pertussis and 2 related conditions. Completed, enrolled 1,564 participants across 19 sites.
Detailed Summary
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP vaccinations. ADACEL® vaccine is currently licensed in the US for persons 11 - 64 years of age, but no pertussis vaccine is yet approved for administration to older adults. The most widely used Td vaccine in the US, DECAVAC®, has no upper limit on its age indication. The purpose of this trial is to describe the safety and immunogenicity of ADACEL® vaccine among individuals ≥ 65 years of age.
Study Details
Timeline
Interventions
0.5 mL, IM
0.5 mL, IM